prospective study has been published that evaluated the effect of smoking on survival in advanced NSCLC treated with chemotherapy. Furthermore, limited data is available on the effect of smoking on chemotherapy toxicity. Considering the high incidence of advanced stage NSCLC and the common use of chemotherapy in these patients, these questions appear to be of major clinical relevance.
Numerous factors have been shown to influence survival and toxicity in patients with advanced NSCLC, such as disease stage, performance status, smoking, age, weight loss, and gender [5, [9] [10] [11] [12] . Additionally, molecular markers such as p53 and ras mutations, and expression of ERCC1, beta-tubulin III and RRM1, have been found to influence treatment outcome [5, [13] [14] [15] .
The main aim of this prospective, observational study was to estimate the effect of prognostic factors, in particular, continued smoking during therapy, on survival in patients with advanced NSCLC receiving gemcitabine-platinum as first-line therapy. Further, prognostic factors identified in previous studies were used to build a survival model with the aim of improving prognosis prediction, in naturalistic clinical settings, in patients with advanced NSCLC who are receiving gemcitabine-platinum as first-line therapy.
Methods

Study Design
This prospective, non-interventional, international, observational study (B9E-AA-B004) was des i g n e d t o e s t i m a t e t h e e f f e c t o f p r o g n o s t i c f a c t o r s , including continued smoking during therapy, on treatment outcomes in patients with advanced NSCLC receiving gemcitabine-platinum as first-line therapy as part of their routine care. To ensure this study reflected real-life clinical practice, all care provided to the patients (including visit frequency, procedures performed at visits, and advice regarding smoking behavior) was at the discretion of the participating oncologist. Patients were recruited between June 2004 and October 2005 from nine countries (China, Egypt, Israel, Pakistan, Poland, Romania, South Korea, Taiwan, and Turkey) and were followed for survival until death, 18 months after the start of treatment, or lost to follow-up. The study was conducted in accordance with the ethics and regulatory r e q u i r e m e n t s o f e a c h c o u n t r y a n d a l l p a r t i c i p a n t s p r o v i d e d w r i t t e n i n f o r m e d c o n s e n t p r i o r t o e n r o l lment in the study.
Participants
Patients were eligible if they: (a) were diagnosed with Stage IIIB or IV NSCLC; (b) were chemonaive; (c) received gemcitabine in combination with platinum (carboplatin or cisplatin) as part of their routine care; (d) had an Eastern Cooperative Oncology Group (ECOG) performance status ≤1; and (e) not simultaneously participating in a gemcitabine-platinum interventional study. The dosing schedule of gemcitabine-platinum therapy, use of concomitant medications, supportive care measures, and all subsequent lines of tumor therapy were at the discretion of the treating oncologist.
Effectiveness and Safety Measures
Eligible participants who received at least one dose of gemcitabine-platinum were evaluated for effectiveness and safety. Effectiveness was measured by s u r v i v a l , d e f i n e d a s t h e t i m e f r o m s t a r t o f gemcitabine-platinum therapy to the date of death due to any cause. T h e e f f e c t o f p r o g n o s t i c f a c t o r s o n a n o c c u rrence of any selected adverse events (AEs; neutropenia, thrombocytopenia, reduced haemoglobin, infection requiring hospitalisation or intravenous antibiotics, respiratory distress syndrome, dyspnea, death, or life-threatening toxicity) and methylation of p16 and RASSF1A were assessed.
Statistical Analyses
Statistical analyses were performed using the SAS program (Version 9, SAS Institute, Cary, NC). A total of 3000 patients were planned to be enrolled with patients allocated in a 3:1 ratio to the Construction:Validation datasets to provide 80% power to draw the conclusion that continued smoking during chemotherapy reduces median survival time by 15% after balancing for clinical characteristics that have a statistically significant effect on survival. To identify potential prognostic factors associated with survival in advanced NSCLC patients treated with first-line gemcitabine-platinum, a total of 42 prognostic factors were analyzed. Some of the factors analyzed in this study were previously identified as potential prognostic factors in NSCLC [17] and include: continued smoking during therapy; number of cigarettes/day during therapy; baseline smoking level; continuing smoker versus ex-smoker; heavy smoker at baseline; never smoked; race; country; disease stage; hypercalcemia; TNM staging (T, N, and M); weight loss >10%; performance status; superior vena cava obstruction present; age <70 years; gemcitabine-platinum regimen; largest tumor >5cm; gender; metastatic disease (extra-thoracic; liver; bone; brain); diagnosis (histology); dyspnea present; cough present; hemoptysis present; pain present; expectoration present; chronic obstructive pulmonary disease present; pleural effusion present; p16 status; RASSF1A status; albumin (normal range indicator); hemoglobin; aspartate aminotransferase (AST/SGOT); alanine aminotransferase (ALT/SGPT); bilirubin (total); albumin; lactic dehydrogenase; calcium. Univariate Cox regression analysis was used to first assess the association between each variable and survival, followed by multivariate stepwise Cox regression analysis for variable selection (with entry and stay cutoff levels of 0.1). If information on any baseline or treatment variable was m i s s i n g i n > 1 0 % o f p a t i e n t s , t h a t v a r i a b l e w a s n o t used to build the primary model. Results are reported as hazard ratios (HR) with 95% confidence intervals.
Additional sensitivity analyses were performed to examine the potential impact of missing data. This involved effect of smoking variables adjusted in multivariate models, also for variables where >10% of the d a t a w a s m i s s i n g u s i n g t h e s a m e m o d e l s e l e c t i o n process described above.
Validation of the final predictive model was assessed using a Cox regression on the Validation dataset with the values of the linear predictor calculated from the coefficients estimated in the Construction dataset [16] . Also, predicted one-year survival was directly compared with the actual one-year survival for patients in the Validation dataset.
The occurrence of AEs and association of p16 and RASSF1A methylation to baseline prognostic factors was analyzed using a univariate and multivariate (stepwise) logistic regression.
Results
Participant Characteristics and Treatments
Baseline clinical and demographic characteristics, including potentially important prognostic factors, are outlined in Table 1 . Of 1214 patients enrolled from nine countries/regions, 891 (73.4%) were assigned to the Construction dataset and 323 (26.6%) to the Validation dataset. Patients were on average 60.5 years of age, with 75.1% being male. Approximately half of the patients had NSCLC of adenocarcinoma origin (48.9%), while approximately two-thirds of p a t i e n t s ( 6 9 . 4 % ) w e r e a s s i g n e d t o gemcitabine-cisplatin treatment. The mean number of gemcitabine-platinum cycles received was 3.76 (95% CI: 3.66, 3.86), with 34.1% of patients receiving no therapy post gemcitabine-platinum treatment. Post gemcitabine-platinum treatment therapies are outlined in Table 2 , with the most common second-line treatment approaches being docetaxel (18.3%) or radiotherapy (17.1%). Of the 1214 patients enrolled, 253 (20.8%) were alive at study completion, 637 (52.5%) had died, 310 (25.5 %) were lost to follow-up, while data was not available for 14 (1.2%). Three hundred and nineteen (26.3%) patients discontinued study therapy due to inadequate response, while 48 (4.0%) discontinued study therapy due to AEs.
Originally, 3000 patients were planned to be enrolled in this study; however, based on slower than expected recruitment, a decision was made to stop accrual after 17 months. At the time, a total of 1214 qualified patients had been enrolled in this study. Abbreviations: ECOG = Eastern Cooperative Oncology Group; N = total number of patients; n = number of patient in specified category; NSCLC = non-small cell lung cancer; SD = standard deviation. 
Effectiveness and Toxicity
The median overall survival time was 12.7 months (95% CI: 11.5, 13.7; n=1213). On completion of study therapy, of the 1214 patients enrolled, 594 (48.9%) had no reported progression of disease. Of the 637 (52.5%) that died during the study, the majority (95.6%), in the opinion of the investigator, died as a result of study disease.
Of the 1214 patients enrolled, 266 (21.9%) reported at least one AE. The most frequently reported A E s w e r e l o w h e m o g l o b i n c o u n t ( < 8 g / d L ; n = 1 6 1 , 13.3%), low neutrophil count (<1.0x10 9 /L associated with fever of ≥38.5°C or documented infection; n=99, 8.2%), and thrombocytopenia (<50x10 9 /L with bleeding; n=73, 6.0%).
Univariate Analyses of Survival
Of 42 prognostic factors analyzed, 16 were found by univariate Cox regression analysis to be significantly (p≤0.05) associated with survival, including baseline smoking level; heavy smoker at baseline; race; country; disease stage; performance status; superior vena cava obstruction; age <70 years; TNM staging; largest tumor >5cm; gender; metastatic liver, bone and brain disease; dyspnea present; chronic obstructive pulmonary disease; albumin (normal range indicator); and lactic dehydrogenase.
Development and Validation of the Predictive Model for Survival
Firstly, all variables (excluding smoking variables) with <10% missing values were included in the initial Cox's model. A stepwise Cox regression was then performed with essential factors identified by Brundage et al (2002) [17] . Country, disease stage, hypercalcemia, "N" factor, weight reduction, performance status, and superior vena cava obstruction were forced into the model. As a result, 6 variables were additionally selected by the regression (gemcitabine-platinum regimen, T-stage, chronic obstructive pulmonary disease, metastatic brain disease, gender, and diagnosis). The final predictive model (Figure 1 ) identified four significant (p≤0.05) and independent predictors of survival, which were disease stage, performance status, gemcitabine-platinum regimen, and T-stage. No smoking variables were represented in the final predictive model.
Cox regression performed on the Validation dataset showed high significance (p=0.0008) of linear predictor calculated using the coefficients estimated in the Construction dataset. Patients in the Validation dataset (n=323) were also classified into three groups based on the predicted one-year survival probabilities forecast from the final predictive model: (1) predicted probability <0.2; (2) predicted probability ranging from ≥0.2 to <0.5; and (3) predicted probability ≥0.5. T h e p r e d i c t e d a n d o b s e r v e d p r o p o r t i o n s s u r v i v i n g were calculated for each of the above groups ( Figure   2 ). These analyses support the predictive model being strongly associated with actual survival in the Validation dataset.
Development of the Predictive Model for Adverse Events
Of 42 prognostic factors analyzed, 6 were found by univariate logistic regression analysis to be signifi c a n t l y ( p ≤ 0 . 0 5 ) a s s o c i a t e d w i t h A E s , w h i c h w e r e country, gemcitabine-platinum regimen, largest tumor >5cm, presence of hemoptysis, presence of pain, and albumin.
The final predictive model, as established in the Construction dataset using multivariate stepwise logistic regression (with gender forced into the model, and excluding smoking variables from the selection process), identified 5 significant (p≤0.05) and indep e n d e n t p r e d i c t o r s o f A E s , t h a t b e i n g d i s e a s e s t a g e (IIIB versus IV), country, weight loss >10%, age <70 years, and the presence of pain. The smoking variables added to the established model did not reach significance (p>0.05).
Effect of Continued Smoking during Therapy on Survival and Adverse Events
Smoking characteristics at baseline and during the study are outlined in Table 3 . Overall, 70.8% of patients had smoked at some point prior to therapy (i.e. ever smokers). Approximately half of ever smokers (53.7%) had ceased smoking at initiation of therapy or within 6 months prior to treatment start, while 11.2% of smokers continued to smoke during therapy. Of those patients continuing to smoke during therapy, the mean number of cigarettes smoked per day was 16.57 (95% CI: 13.0, 20.1). There was no statistically significant difference in survival observed between "never smokers" and "ever smokers", with a n u n a d j u s t e d H R ( v e r s u s n e v e r s m o k e r s ) o f 1 . 
Association of p16 and RASSF1A Methylation Status to Baseline Prognostic Factors and Adverse Events
Methylation status of p16 and RASSF1A was analyzed in 86 patients, with hypermethylation observed in 15 (17.4%, p16) and 8 (9.3%, RASSF1A) patients, respectively. Thirty-nine prognostic factors were analyzed by univariate and multivariate (stepwise) logistic regression. In those with RASSF1A hypermethylation, no factors were identified as significant following univariate (n=86) and stepwise logistic regression (n=65). In those with p16 hypermethylation, the following factors were found to be sig- Neither p16 nor RASSF1A were significant when added to the established predictive model for AEs. Additionally, the univariate logistic regression did not identify methylation factors as predictive of AEs.
Discussion
In this prospective, observational study, the eff e c t o f p r o g n o s t i c f a c t o r s , i n p a r t i c u l a r c o n t i n u e d smoking during therapy, on survival and other treatment outcomes, was assessed in patients with advanced NSCLC receiving gemcitabine-platinum as first-line therapy. Continued smoking during gemcitabine-platinum therapy was not associated with shorter survival in patients with advanced NSCLC. Construction and validation of a predictive model identified four independent prognostic factors associated with survival: disease stage, performance status, gemcitabine-platinum regimen, and T-stage.
The greatest risk factor associated with lung cancer is cigarette smoking [18] [19] , with approximately 85% of all lung cancer cases in men and 47% in women attributed to tobacco smoking [1] . Previous studies have identified an association towards longer survival [19] , as well as statistically significant differences in survival [20] , between "never smokers" and "ever smokers" who have undergone chemotherapy. Our study had a similar proportion of never smokers (25.7%) compared to previous studies (14.5% [21] ; 16% [20] ; 36.3% [19] ). However, unlike these other studies, there was no statistically significant difference in survival observed between "never smokers" and "ever smokers" receiving gemcitabine-platinum as first-line therapy. A retrospective study by Nguyen et al (2006) in which exploratory subgroup analyses were performed, reported similar findings to this study, in which no significant difference in median survival time between "ever smokers" and "never smokers" was observed in patients receiving gemcitabine-cisplatin therapy [22] . However, gemcitabine-cisplatin was also a therapy utilized in the study by Scagliotti et al (2008) and an association towards longer survival was observed in "never smokers" (15.3 months) compared to "ever smokers" (10.3 months) [21] . I n t e r m s o f c o n t inued smoking during therapy, in our study, fewer patients (11.2%) continued smoking during therapy when compared to a previous study (48%) [20] . It is interesting to note that the retrospective study of Tsao et al (2006) encompassed patients treated with first-line chemotherapy between 1993 and 2002 [20] , while our study reflects patient treatment during 2004-2005. It is t h e r e f o r e p o s s i b l e t h a t t h e l o w e r p r o p o r t i o n o f p at i e n t s c o n t i n u i n g t o s m o k e d u r i n g t h e r a p y i n o u r study reflects the increased influence that oncologists are having on their patients as well as a greater public awareness of the association between smoking and lung cancer. Despite differences in the proportion of patients continuing smoking during therapy, similar findings in terms of the impact of continued smoking during therapy on survival were noted between our study and Tsao et al (2006) , with no statistically significant difference in survival observed between those patients continuing to smoke during therapy and those who discontinued prior to therapy initiation [20] . This suggests the detrimental effects of cigarette s m o k i n g m a y o c c u r e a r l i e r i n d i s e a s e p rogression. Another explanation may be that the effects of continued smoking during therapy are not evident in patients treated with chemotherapy in late stage dise a s e a s t h e i r d u r a t i o n o f s u r v i v a l i s l i m i t e d . Additionally, bias as a result of the non-randomized, unblinded design of the study and confounding are inherently associated with observational studies and should be considered when interpreting the results. The effect of continued smoking during therapy on toxicity was also analyzed in this study. Although an a s s o c i a t i o n t o w a r d s a g r e a t e r r a t e o f A E s w a s o bserved in patients who continued to smoke during therapy, this was not statistically significant.
In addition to smoking, numerous factors have been shown to influence survival and toxicity in patients with advanced NSCLC, such as disease stage, p e r f o r m a n c e s t a t u s , a g e , w e i g h t l o s s , a n d g e n d e r [5, [9] [10] [11] [12] [19] [20] . In this study, development of a predictive model in a Construction dataset, and subsequent validation with a Validation dataset, led to the identification of four significant (p≤0.05) and independent predictors of survival, which were disease stage (IV versus IIIB), performance status (ECOG 1 versus 0), gemcitabine-platinum regimen (carboplatin versus cisplatin), and T-stage (versus T1). Performance status has been shown in a number of trials to be a powerful predictor of survival [9, 11, [19] [20] [23] [24] [25] . Similarly, in t h i s s t u d y , p e r f o r m a n c e s t a t u s w a s i d e n t i f i e d a s a n independent prognostic factor, with improved survival associated with a better baseline performance status. In this study, disease stage was also identified as an independent prognostic factor, with improved s u r v i v a l n o t e d i n t h o s e p a t i e n t s w i t h G r a d e I I I B NSCLC when compared with Grade IV disease. Similar findings have been shown in other studies [19, 24] . T-stage was also shown to be an independent prognostic factor in our study, with improved survival observed in patients with T1 stage compared with T2-TX. Hence, in relation to TNM the prognostic value in terms of survival prediction, in our study, can be b a s e d o n T -stage alone. This is in alignment with ASCO guidelines [26] . Although platinum combinations with a third-generation chemotherapy agent are w i d e l y r e c o g n i z e d a s s t a n d a r d o f c a r e f o r f i r s t -line treatment of patients with advanced NSCLC, the choice of platinum agent (carboplatin or cisplatin) varies. In our study, the choice of platinum agent was shown to influence survival, with cisplatin proving to b e m o r e e f f e c t i v e t h a n c a r b o p l a t i n . This finding is consistent with a meta-analysis, in which carboplatin combinations with third-generation chemotherapy were shown to be inferior to cisplatin combinations with third-generation chemotherapy [27] .
Genetic factors are also involved in lung cancer development, with aberrant promoter methylation playing an important role. Previous studies of NSCLC have reported varied frequencies of p16 methylation, with Wang et al (2008) reporting p16 methylation in 38% of samples [28] , while Guzman et al (2007) observed p16 methylation in 79.7% of samples [29] . In this study, the p16 methylation observed was low (17.6%) compared to observations in previous studies. Additionally, RASSF1A methylation has been implicated in NSCLC, with RASSF1A methylation reported in 21% [28] and 40% [30] o f s a m p l e s , w h i l e i n t h e current study RASSF1A was observed in only 8.2% of samples. Possible explanations for the different methylation frequencies include techniques to study methylation status and study population. Wang et al (2008) [28] utilized microarray technology, while Guzman et al (2007) [29] , Li et al (2003) [30] and the current study utilized PCR-based technology. These studies focused on samples from China [28] , Chile [29] and the US [30] , respectively, whereas the current study analyzed samples from nine different countries (China, Egypt, Israel, Pakistan, Poland, Romania, South Korea, Taiwan, and Turkey). Moreover, different frequencies of methylation have been observed in different NSCLC histological types [29] , thus diff e r e n t p r o p o r t i o n s o f h i s t o l o g i c a l t y p e s m a y b e present in each of the different studies.
The naturalistic setting of this study provides insight into the use of gemcitabine-platinum first-line therapy and treatment outcomes. In addition to the strengths of this study, we acknowledge several limitations which should be taken into account when interpreting the results. F i r s t l y , a s t h e n u m b e r o f p at i e n t s e n r o l l e d i n t h i s s t u d y w a s r e d u c e d ( n = 1 2 1 4 ) c o m p a r e d w i t h t h e p l a n n e d n u m b e r ( n = 3 0 0 0 ) t h e study was not adequately powered to test the hypothesis that smoking during chemotherapy may be associated with shorter survival in patients with advanced NSCLC who receive first-line chemotherapy with gemcitabine-platinum. Secondly, there was a higher than anticipated decrease in smoking during therapy. T h i r d l y , t h e o b s e r v a t i o n a l n a t u r e o f t h e study can lead to bias and confounding.
Conclusions
This observational study shows that continued smoking during gemcitabine-platinum therapy was not associated with shorter survival in patients with advanced NSCLC. Additionally, construction and validation of a predictive model identified four independent prognostic factors that were associated with survival -disease stage, performance status, gemcitabine-platinum regimen, and T-stage.
